Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy— A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy— A systematic review and meta-analysis

Published:2022-03 Issue: Volume:236 Page:108927
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Li Haifeng,Ni Mengqian,Xue Cong,Li Lu,Huang Riqing,Yang Wei,Hu Anqi,An Xin,Shi Yanxia

Funder

National Natural Science Foundation of China

Science and Technology Planning Project of Guangdong Province

Young Teacher Foundation of Sun Yat-sen University

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference23 articles.

1. Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2;Sakr;Biomed. Pharmacother.,2015

2. Current strategies and novel therapeutic approaches for metastatic urothelial carcinoma;Mollica;Cancers (Basel),2020

3. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: current paradigms and emerging treatment options;Koufopoulou;Cancer Treat. Rev.,2020

4. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC);Bamias;Ann. Oncol.,2019

5. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma;Galsky;Ann. Oncol.,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials;Clinical Genitourinary Cancer;2024-10

2. New insights into ATR inhibition in muscle invasive bladder cancer: The role of apolipoprotein B mRNA editing catalytic subunit 3B;Oncology Research;2024

3. The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma;Cancer Medicine;2023-11-21

4. Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis;Current Oncology;2023-11-17

5. Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis;Clinical Genitourinary Cancer;2023-10